Drug Profile
Research programme: biotherapeutics - Eli Lilly and Company/GlycoFi
Latest Information Update: 14 Apr 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; GlycoFi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Nov 2005 Preclinical trials in Undefined in USA (unspecified route)